6/27/2025

As the United Kingdom's FTSE 100 index faces downward pressure due to weak trade data from China, investors are closely monitoring market conditions that have impacted sectors tied to global demand. In such a fluctuating environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for those looking to capitalize on undervaluation amidst broader economic uncertainties.

Source: Yahoo

6/27/2025

When Pascal Soriot flew in to speak at the Boao Forum in China this year, many expected him to keep a low profile. With Donald Trump and Xi Jinping firing shots at each other in an ever-escalating trade row, it was presumed that the AstraZeneca boss would want to keep his head down.

Source: Yahoo

6/26/2025

Source: SeekingAlpha

6/26/2025

President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. But will it work? And will biotech stocks take a hit?

Source: Yahoo

6/26/2025

The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Source: Yahoo

6/26/2025

ISELIN, N.J., June 26, 2025--Ephicacy Consulting Group, Inc. has announced the addition of Névine Zariffa to the board.

Source: Yahoo

6/26/2025

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines due to weak trade data from China, highlighting concerns over global economic recovery. As investors navigate these turbulent times, identifying undervalued stocks becomes crucial; such stocks may offer potential opportunities by trading below their intrinsic value amidst broader market uncertainties.

Source: Yahoo

6/25/2025

IonQ (NYSE:IONQ) made headlines with the first known simulation of neutrinoless double-beta decay using its quantum computer, highlighting groundbreaking scientific achievements that suggest quantum computers could unlock new realms in fundamental physics processes. The company's stock price surged 73% over the last quarter, likely bolstered by this announcement. Other developments, such as collaborations with AstraZeneca and NVIDIA, and strides in quantum computing applications in...

Source: Yahoo

6/25/2025

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non-small cell lung cancer, adding to its robust oncology portfolio. Despite this advancement, AstraZeneca's share price remained flat over the past month, in contrast to a broader market rise of 1.9% in recent days. Continued approvals for Calquence in the EU and positive trial results like those for ENHERTU in breast cancer may have provided additional support to the...

Source: Yahoo

6/25/2025

Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its portfoilio.

Source: Yahoo

6/25/2025

AstraZeneca (NASDAQ:AZN) is one of the most active stocks to buy according to analysts. On June 16, the preliminary results for AstraZeneca’s surovatamig, a next-gen CD19xCD3 bispecific T-cell engager (BiTE), were presented at the 2025 Congress of the European Hematology Association (EHA 2025). The event was held from June 12 to 15 in Milan, Italy. […]

Source: Yahoo

6/25/2025

LIVERPOOL, United Kingdom, June 25, 2025 (GLOBE NEWSWIRE) -- Human Magic, the global employer brand agency behind creative strategies for brands like Nike, Microsoft, Apple, LinkedIn, and AstraZeneca, today announces that TapIn, the award-winning Gen Z-focused creative agency, is joining its rapidly growing global agency. The move strengthens Human Magic’s creative and cultural reach for global clients, bringing deeper expertise in social-first content, inclusive recruitment marketing, and youth

Source: Yahoo

6/24/2025

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Source: Yahoo

6/24/2025

FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.

Source: Yahoo

6/24/2025

WILMINGTON, Del., June 24, 2025--DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.

Source: Yahoo

6/24/2025

Continued approval depends on further confirmation and detailed clinical benefit from a study.

Source: Yahoo

6/24/2025

Investing.com -- AstraZeneca (NASDAQ:AZN) on Monday night received accelerated approval from the U.S. Food and Drug Administration (FDA) for its lung cancer drug Datroway.

Source: Yahoo

6/24/2025

In the last week, the United Kingdom market has been flat, yet it has shown a 4.0% increase over the past year with earnings forecasted to grow by 14% annually. In this context of steady growth and positive earnings projections, identifying stocks that may be trading below their fair value could present potential investment opportunities for those looking to capitalize on undervalued assets.

Source: Yahoo

6/24/2025

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a Phase 2 trial. The approval was also supported by data from a Phase 3 trial.

Source: Yahoo

6/23/2025

GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.

Source: Yahoo